How GLP-1 Medications Work for Weight Loss

“How does Ozempic actually work?” is one of the most common questions people ask online about weight-loss medications, usually followed by a second one: “Is it just making me feel sick, or is something real happening?” Both are fair. “It controls your appetite” hides some elegant biology and some important limits.

This article goes one level deeper than our plain-English GLP-1 explainer. It walks through what happens from the moment a dose enters the body: why the natural hormone vanishes in minutes while the drug lasts a week, which brain circuits it reaches, how much less people really eat, what happens in the stomach, what the lost weight is made of, and why the effect fades when treatment stops.

Educational only. This is not medical advice. Do not start, stop or change a GLP-1 medication, or its dose, without guidance from a licensed clinician who knows your health history.

The short answer: GLP-1s make a calorie deficit feel manageable

GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and the dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) cause weight loss mainly by reducing how much people want to eat and how much they eat. The FDA labels for Wegovy and Zepbound say it plainly: the drug “decreases calorie intake,” and “the effects are likely mediated by affecting appetite.”

Everything else (slower stomach emptying, better blood-sugar control, effects on food preferences) either supports that central effect or is a side benefit. The drugs do not melt fat, and they do not meaningfully raise metabolic rate. They make it easier for the body to run a sustained energy deficit, which is the same physics behind every weight-loss method. We explain that physics in calories in, calories out, explained.

Step 1: Your own GLP-1 is a fleeting signal

GLP-1 (glucagon-like peptide-1) is made by L-cells in the lining of the gut, which are most dense in the lower small intestine and colon, and by a small group of neurons in the brainstem. When you eat, nutrients such as glucose, fats and protein trigger L-cells to release GLP-1.

Natural GLP-1 is extremely short-lived. A 2019 review in Molecular Metabolism by leading GLP-1 researchers notes that native GLP-1 has a half-life of around 1–2 minutes, because an enzyme called DPP-4 (dipeptidyl peptidase-4) chops it apart and the kidneys clear it. Much of it is degraded before it ever leaves the gut: the review estimates that only about 10–15% of active GLP-1 reaches the general circulation.

That is why a meal does not produce anything like the appetite effect of a GLP-1 medication: the natural signal is a brief local whisper, and the drugs turn it into a week-long broadcast.

Step 2: How the drugs were engineered to last a week

Drug designers solved the “two-minute problem” with a few chemical changes. According to the Wegovy label and the semaglutide studies:

• Semaglutide shares 94% of its amino-acid sequence with human GLP-1, so it fits the same receptor.
• An amino-acid swap makes it resistant to DPP-4, the enzyme that destroys natural GLP-1.
• A C18 fatty-acid chain lets it bind tightly to albumin, a common blood protein. The label says semaglutide is more than 99% albumin-bound, which reduces kidney clearance and protects it from breakdown.

Tirzepatide uses a similar trick with a C20 fatty diacid that “enables albumin binding and prolongs the half-life,” per the Zepbound label.

Feature	Natural GLP-1	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
Receptors activated	GLP-1	GLP-1	GIP and GLP-1
Half-life	About 1–2 minutes	About 1 week	About 5 days
Albumin binding	Minimal	More than 99%	About 99%
How long it lingers after the last dose	Minutes	About 5–7 weeks (label)	Not stated in the same way on the label
Typical dosing	Released with meals	Once weekly injection (a daily pill version also exists)	Once weekly injection

That long half-life has a practical consequence: the drug’s effect builds over weeks, and it also takes weeks to wash out. The Wegovy label notes semaglutide “will be present in the circulation for about 5 to 7 weeks after the last dose of 2.4 mg.” This is one reason labels use a gradual step-up schedule rather than starting at the full dose. Dose schedules are a clinician’s decision; see our GLP-1 Guide hub for the starting-treatment section.

Step 3: What GLP-1 drugs do in the brain

The single most important site of action is the brain. Both the Wegovy and Zepbound labels state that GLP-1 receptors are present in brain areas involved in appetite regulation, and that in animal studies the drugs reached and activated neurons in those regions. Much of the detailed map comes from rodent research, so it is best read as a well-supported model rather than proven human anatomy.

Where the drug gets in

A 2020 study in JCI Insight tracked fluorescently labeled semaglutide in mice. Semaglutide did not cross the blood-brain barrier in general. Instead it entered through “circumventricular organs,” small brain regions with leakier blood vessels, and a few sites next to the fluid-filled ventricles, including:

• the arcuate nucleus of the hypothalamus, a master control center for hunger and fullness,
• the area postrema and nucleus tractus solitarius (NTS) in the brainstem, which process signals from the gut and are also involved in nausea, and
• the lateral septum, linked to food motivation.

What it switches on and off

In the arcuate nucleus, semaglutide activated POMC/CART neurons, which promote fullness, and inhibited NPY/AgRP neurons, which drive hunger. Brain-activity mapping also showed secondary activation of the lateral parabrachial nucleus, a relay station that helps end meals. The authors concluded that semaglutide works through “diverse GLP-1R populations” and pathways involved in food intake and reward, rather than one single switch.

A short, clinician-made animation from the Calgary Guide video series, presented by Dr. Yan Yu on YouTube (“GLP-1 RAs – How They Work”), walks through this same hypothalamus pathway (NPY/AgRP down, POMC up), plus the stomach and pancreas effects, in about five minutes. It is a useful visual companion to this section.

Hunger, cravings and “food noise”

People on these drugs often describe quieter “food noise”: fewer intrusive thoughts about eating. Online, there is a lively debate about whether food noise is just hunger by another name. The human research supports something broader than plain hunger. In a 12-week trial published in Diabetes, Obesity and Metabolism in 2017, semaglutide was associated with:

• less hunger and fewer food cravings,
• “better control of eating,” measured with a validated questionnaire, and
• a lower preference for high-fat, non-sweet foods such as savory snacks.

“Food noise” itself is a patient term and was not a measured endpoint in those trials, but appetite, craving and control-of-eating scores were.

Step 4: How much less do people actually eat?

This is where the mechanism becomes measurable. Two small, carefully controlled studies let participants eat freely (“ad libitum”) from buffet-style meals and weighed what they ate.

Study	Dose and length	What was measured	Result vs placebo
Blundell et al., 2017 (30 adults with obesity, crossover)	Semaglutide 1.0 mg weekly, 12 weeks	Total intake across lunch, dinner and evening snacks	About 24% lower (−3,036 kJ, roughly 725 kcal less over the test day)
Blundell et al., 2017	Same	Lunch only	About 35% lower
Friedrichsen et al., 2021 (72 adults with obesity)	Semaglutide 2.4 mg weekly, 20 weeks	Lunch only	35% lower (1,736 vs 2,676 kJ, roughly 415 vs 640 kcal)

One detail matters a lot: in the 2017 study, nausea ratings were similar on semaglutide and placebo, so the authors attributed the lower intake to effects on appetite and eating control rather than to feeling sick. Participants also lost about 5 kg over 12 weeks, mostly fat. Both studies were funded by the drug’s manufacturer, as was much of the early mechanistic work, so independent replication is welcome.

Step 5: The stomach effect is real, but it fades

GLP-1 slows gastric emptying: food leaves the stomach more slowly, so you feel full sooner. This is real, and it is a major reason for early side effects such as nausea, bloating and reflux. Our guide to GLP-1 nausea covers how to manage it.

What is less well known is that the stomach effect seems to weaken with continued treatment:

• The Zepbound label says tirzepatide’s delay in gastric emptying “is largest after the first dose and this effect diminishes over time.” After a first 5 mg dose, peak acetaminophen levels (a marker of how fast the stomach empties) were 55% lower; by week 6 on 15 mg there was “no meaningful impact.”
• In the 20-week semaglutide 2.4 mg study, the authors found “no evidence of delayed gastric emptying at week 20,” assessed indirectly with the same acetaminophen method.

The Wegovy label still lists delayed gastric emptying as an effect of semaglutide, and the slowing matters for some situations, such as how other oral medicines are absorbed and planning for anesthesia, which is why you should always tell clinicians you take one. But the long-term appetite effect appears to come mostly from the brain, not from a permanently full stomach.

Step 6: Insulin, glucagon and blood sugar

GLP-1 is an incretin, a gut hormone that amplifies insulin release after meals. The labels state that semaglutide and tirzepatide stimulate insulin secretion and reduce glucagon secretion in a glucose-dependent manner, meaning the effect is strongest when blood sugar is high. The Zepbound label adds that tirzepatide increased insulin sensitivity in a clamp study in people with type 2 diabetes.

These effects explain why the same molecules treat type 2 diabetes. For weight, they are mostly supportive rather than the main driver: lower insulin does not by itself force fat loss without a calorie deficit.

Do GLP-1s speed up metabolism?

Not in any meaningful way, based on current human data. In the 2017 semaglutide study, resting metabolic rate was lower on semaglutide, but after adjusting for lean body mass the difference was not significant. The authors concluded that weight loss “was not attributable to increased energy expenditure” and “most likely” came from reduced intake.

The safest summary: GLP-1s work on the “calories in” side of the equation.

What about tirzepatide’s GIP component?

Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The Zepbound label says GLP-1 is “a physiological regulator of appetite and caloric intake” and that “nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake.” Both receptor types are found in appetite-related brain areas.

Average results in the pivotal 72-week SURMOUNT-1 trial (Study 1 in the label) were −15.0%, −19.5% and −20.9% body weight at 5, 10 and 15 mg, versus −3.1% on placebo. In STEP 1 (Study 2 in the Wegovy label), semaglutide 2.4 mg produced −14.9% at 68 weeks versus −2.4% on placebo. These were separate trials with different populations, so they should not be read as a head-to-head comparison. For a fuller comparison, see semaglutide vs tirzepatide, and our profiles of semaglutide and tirzepatide.

What is the lost weight made of?

Both labels say the drugs lower body weight “with greater fat mass loss than lean mass loss.” The best human detail comes from a DXA body-composition substudy of 140 STEP 1 participants:

• Total fat mass fell 19.3% from baseline with semaglutide.
• Visceral (deep belly) fat fell 27.4% in the regions measured.
• Lean body mass fell 9.7%, but because fat fell faster, the share of lean mass in the body rose by 3.0 percentage points.

Losing some lean tissue is a normal part of large weight loss with any method. It is also why nutrition societies emphasize enough protein and resistance training during treatment. See how much protein you need on a GLP-1 and our high-protein eating guide.

Why weight loss eventually plateaus

Nobody keeps losing weight forever on a GLP-1. The body defends its weight through two feedback loops that NIH researchers Kevin Hall and Juen Guo describe in a 2017 Gastroenterology review:

1. Energy expenditure falls as body size shrinks, and sometimes by more than expected (“metabolic adaptation”).
2. Appetite rises as weight is lost. In one study they cite, people increased intake by about 100 kcal per day for every kilogram lost, an effect more than three times larger than the drop in expenditure.

A GLP-1 pushes back against the second loop, which helps explain why the drugs produce larger losses than diet alone. But eventually a new balance point is reached, where reduced intake matches reduced expenditure. That is a plateau, not a failure. Our plateaus and maintenance hub covers what clinicians look at next.

Why weight returns when the medicine stops

If the drug works by sending an artificial fullness signal, removing the drug removes the signal. Randomized withdrawal trials show this clearly:

Trial (label name)	Design	After switching to placebo	Continued drug
Semaglutide, STEP 4 (Wegovy Study 5)	20 weeks on semaglutide, then randomized for 48 weeks	Weight rose 6.9% from week 20 to 68	Weight fell a further 7.9%
Tirzepatide, SURMOUNT-4 (Zepbound Study 4)	36 weeks on tirzepatide (average −20.9%), then randomized for 52 weeks	Weight rose 14.0%	Weight fell a further 5.5%

People who stop are not “failing.” Their biology is doing what the feedback loops above predict once the medication’s appetite signal fades over the weeks it takes to clear. This is why obesity is increasingly treated as a chronic condition, and why decisions about how long to stay on treatment belong with a clinician. Our GLP-1 Guide hub has a long-term-use section.

The mechanism at a glance

Effect	Where it happens	How strong the human evidence is
Less hunger, more fullness, fewer cravings	Hypothalamus and brainstem (mapped mainly in animals)	Strong: measured lower intake in controlled studies
Lower preference for fatty, savory foods	Brain reward and appetite circuits	Moderate: questionnaire and food-choice tests
Slower stomach emptying	Stomach and gut nerves	Strong early on, then fades
More insulin, less glucagon when glucose is high	Pancreas	Strong (basis of diabetes use)
Higher metabolic rate	—	Not shown in humans
Fat lost faster than lean tissue	Whole body	Moderate: DXA substudies

What this means if you are considering a GLP-1

Understanding the mechanism leads to some practical, non-prescriptive takeaways:

• Food quality still matters. If you will be eating less, each meal needs to carry more protein, fiber and micronutrients.
• Early side effects often ease as the stomach effect fades, but tell your clinician if they do not.
• Strength training and protein help protect lean mass during a large deficit.
• Plan for the long term. The drug works while it is present; a maintenance plan is part of the conversation from day one.
• Approved products matter. The mechanism depends on a precisely engineered molecule. Compounded versions are not FDA-approved; see which GLP-1s are FDA-approved.

Questions to ask your clinician

1. Which medication fits my health history, and why?
2. How will we judge whether it is working for me?
3. Which side effects should prompt a call, and which usually pass?
4. How should I adjust protein and activity while my appetite is lower?
5. What is our plan if I need or want to stop?

Our first 30 days guide covers the early weeks in more detail.

The bottom line

GLP-1 medications take a gut hormone that normally lasts a minute or two and, through clever chemistry, keep its signal running for about a week. That signal reaches appetite and meal-ending circuits in the brain, quiets hunger and cravings, briefly slows the stomach, and improves blood-sugar handling. The result, in controlled studies, is that people choose to eat roughly a quarter to a third less, and the weight loss follows from that sustained deficit. The drugs do not burn fat directly, the stomach effect fades, and the appetite effect fades when treatment stops, which is why regain is common afterward.

Keep exploring in the GLP-1 Guide and the Fat Loss Basics hub.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical advice, diagnosis or treatment. Never start, stop or change a medication without talking to a licensed clinician.